Leerink Partnrs Has Bullish Estimate for Immunic Q2 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Immunic in a research report issued on Tuesday, June 3rd. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic's Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.51) EPS and FY2026 earnings at ($0.34) EPS.

A number of other research firms have also issued reports on IMUX. D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Thursday. William Blair reiterated an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. B. Riley reiterated a "buy" rating and issued a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd. Wall Street Zen lowered shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $11.60.

Immunic Stock Up 2.0%

Shares of IMUX stock traded up $0.02 during trading hours on Thursday, reaching $0.79. 2,456,208 shares of the stock traded hands, compared to its average volume of 864,728. Immunic has a 1-year low of $0.56 and a 1-year high of $2.11. The business has a fifty day moving average price of $0.96 and a 200 day moving average price of $1.05. The firm has a market capitalization of $75.54 million, a PE ratio of -0.64 and a beta of 1.48.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25).

Institutional Trading of Immunic

Several large investors have recently modified their holdings of IMUX. Aberdeen Group plc bought a new stake in shares of Immunic during the 1st quarter worth $1,155,000. Millennium Management LLC boosted its holdings in shares of Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after buying an additional 479,846 shares during the period. Focus Partners Wealth boosted its holdings in shares of Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after buying an additional 415,104 shares during the period. 683 Capital Management LLC boosted its holdings in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after purchasing an additional 200,000 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after purchasing an additional 177,542 shares during the period. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.